Eton Pharmaceuticals (NASDAQ:ETON) Issues Earnings Results, Misses Expectations By $0.07 EPS

Eton Pharmaceuticals (NASDAQ:ETON) released its quarterly earnings data on Thursday. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.07), Zacks reports. The business had revenue of $21.28 million for the quarter, compared to analysts’ expectations of $20.58 million. Eton Pharmaceuticals had a negative net margin of 9.50% and a negative return on equity of 11.32%.

Here are the key takeaways from Eton Pharmaceuticals’ conference call:

• 2025 revenue and profitability accelerated materially—Q4 product revenue was $21.3M (up 83% YoY), adjusted EBITDA margin improved to 29%, and management guides 2026 revenue >$110M with adjusted EBITDA ≥30%.
• DESMODA launch — the FDA‑approved oral liquid desmopressin (no age restriction) launched quickly and has shown early traction; management reiterates $30M–$50M peak sales guidance and estimates ~ $80k net revenue per patient per year.
• HEMANGEOL acquisition ($14M cash) will be relaunched May 1 with a shift to Eton’s rare‑disease distribution model, a zero copay program, and seven dedicated hires, which management expects to materially improve margins and make it a top product by 2027.
• Near‑term cash and SG&A pressure — Q4 included a $11.6M operating cash outflow driven by Medicaid rebates and $3.5M in FDA program fees, leaving $25.9M cash on hand, while FDA fees and HEMANGEOL are expected to add roughly $6.3M of incremental SG&A in 2026.
• Pipeline and label expansion milestones progressing—Increlex protocol submitted (first patient targeted in Q3), KHINDIVI bioequivalence study dosed (supplement expected in Q3 with potential mid‑2027 launch), and an ET‑700 PET study begins in April; these could be meaningful upside but carry execution and timing risk.

Eton Pharmaceuticals Stock Up 9.2%

ETON stock opened at $20.77 on Friday. The stock has a 50-day simple moving average of $16.59 and a two-hundred day simple moving average of $17.34. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19. Eton Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $23.00. The firm has a market capitalization of $557.05 million, a PE ratio of -83.08 and a beta of 1.19.

Analyst Ratings Changes

ETON has been the subject of several recent research reports. Craig Hallum lifted their target price on shares of Eton Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Wall Street Zen cut shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th. HC Wainwright lifted their price objective on shares of Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Zacks Research raised shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $31.00.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Soleus Capital Management L.P. purchased a new stake in Eton Pharmaceuticals in the 2nd quarter worth approximately $4,061,000. Millennium Management LLC grew its position in shares of Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after purchasing an additional 217,042 shares in the last quarter. Oberweis Asset Management Inc. purchased a new position in shares of Eton Pharmaceuticals during the 3rd quarter valued at $4,180,000. BNP Paribas Financial Markets increased its holdings in shares of Eton Pharmaceuticals by 162.0% in the third quarter. BNP Paribas Financial Markets now owns 229,790 shares of the company’s stock worth $4,993,000 after purchasing an additional 142,094 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Eton Pharmaceuticals by 114.5% in the second quarter. JPMorgan Chase & Co. now owns 242,580 shares of the company’s stock worth $3,457,000 after purchasing an additional 129,467 shares during the period. Hedge funds and other institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.